NASDAQ: CCCCC4 Therapeutics Inc Stock Ownership - Who owns C4 Therapeutics?
Insider buying vs selling
Have C4 Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Kenneth Carl Anderson | Director | 2024-04-01 | 1,389 | $8.10 | $11.25kBuy |
| Donna Roy Grogan | Director | 2024-04-01 | 1,697 | $8.10 | $13.75kBuy |
| Glenn Dubin | Director | 2024-04-01 | 1,358 | $8.10 | $11.00kBuy |
| Andrew Hirsch | President CEO | 2024-02-15 | 6,560 | $7.90 | $51.82kSell |
| Kendra Adams | Chief Financial Officer | 2024-02-13 | 1,301 | $6.53 | $8.50kSell |
| Scott N. Boyle | Chief Business Officer | 2024-02-13 | 1,735 | $6.53 | $11.33kSell |
| Stewart Fisher | Chief Scientific Officer | 2024-02-13 | 2,255 | $6.53 | $14.73kSell |
| Kelly Schick | Chief People Officer | 2024-02-13 | 1,735 | $6.53 | $11.33kSell |
| Jolie Siegel | Chief Legal Officer | 2024-02-13 | 1,735 | $6.53 | $11.33kSell |
| Donna Roy Grogan | Director | 2024-01-02 | 2,108 | $6.52 | $13.74kBuy |
CCCC insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when CCCC insiders and whales buy or sell their stock.
CCCC Shareholders
What type of owners hold C4 Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Marc A. Cohen | 12.11% | 8,308,874 | $53.76M | Insider |
| Wasatch Advisors LP | 10.41% | 7,138,949 | $46.19M | Institution |
| Alain J. Cohen | 8.88% | 6,094,001 | $39.43M | Insider |
| Ra Capital Management LP | 7.11% | 4,878,000 | $31.56M | Institution |
| Commodore Capital LP | 5.54% | 3,800,000 | $24.59M | Institution |
| Lynx1 Capital Management LP | 4.57% | 3,134,396 | $20.28M | Institution |
| Price T Rowe Associates Inc | 3.73% | 2,558,480 | $16.55M | Institution |
| Arrowmark Colorado Holdings LLC | 3.12% | 2,137,381 | $13.83M | Institution |
| Vanguard Group Inc | 2.91% | 1,999,401 | $12.94M | Institution |
| Point72 Asset Management LP | 2.86% | 1,961,359 | $12.69M | Institution |
CCCC vs Biotech Stocks
C4 Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.